ADMA Biologics, Inc., was incorporated as a New Jersey corporation on June 24, 2004 and re-incorporated in Delaware on July 16, 2007. The Company is an end-to-end commercial biopharmaceutical company headquartered in the United States that manufactures, markets and develops specialty biological products for immunodeficient patients and populations at risk for specific infectious diseases. It sells three FDA-approved products — ASCENIV, BIVIGAM and Nabi-HB — which are manufactured at its Florida facility and operate an FDA-licensed plasma collection center. 

Expected P&L on Expiry

Key Stats

Pricing Model

About ADMA20260417C10